Fate Therapeutics

Quarterly Financials

Values in thousands2025-12-312025-09-302025-06-302025-03-31
Revenue
$1,369
$1,741
$1,907
$1,629
Gross Profit
-5,277
1,741
1,907
1,629
EBITDA
-42,212
-29,023
-30,792
-37,947
EBIT
-32,374
-32,250
-34,070
-41,280
Net Income
-32,374
-32,250
-34,070
-37,621
Net Change In Cash
1,369
1,741
1,907
1,629
Free Cash Flow
-24,506
-26,577
-25,949
-35,005
Cash
46,628
40,622
41,249
44,920
Basic Shares
118,789
118,998
118,528
118,375

Annual Financials

Values in thousands2025-12-312024-12-312023-12-312022-12-31
Revenue
$6,646
$13,631
$63,533
$96,300
Gross Profit
13,631
-93,654
96,300
EBITDA
-127,020
-176,577
-172,229
-294,628
EBIT
-136,315
-195,539
-190,511
-308,386
Net Income
-136,315
-186,262
-160,928
-255,056
Net Change In Cash
6,646
13,631
63,533
96,300
Free Cash Flow
-112,037
-123,604
-138,416
-283,774
Cash
46,628
36,056
41,870
61,333
Basic Shares
118,789
113,685
98,411
96,826

Earnings Calls

QuarterEPS
2025-12-31
-$0.27
2025-09-30
-$0.27
2025-06-30
-$0.29
2025-03-31
-$0.32